• SEC Filings

On February 22, 2018, Jason Keyes resigned as Executive Vice President and Chief Financial Officer of Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) to pursue another business opportunity, with such resignation effective as of February 23, 2018.

On February 27, 2018, the Company appointed Monica Forbes as Vice President and acting Chief Financial Officer to serve as the Company’s principal financial officer, and appointed Stephen Moglia, the Company’s current Vice President and Chief Accounting Officer, to serve as the Company’s principal accounting officer, with each appointment effective as of February 24, 2018.

Ms. Forbes, age 42, joined Orexigen in October 2014 as the Company’s Senior Director of Financial Planning and Analysis, with primary responsibility for financial budgeting and forecasting.Prior to joining Orexigen, Ms. Forbes served as Associate Director of Financial Planning and Analysis at Amylin Pharmaceuticals, Inc. from April 2008 to June 2014.Prior to that, she served as a Manager of HR Analytics at Invitrogen Corporation from April 2006 to April 2008, as a Senior Marketing Analyst at Ericsson Inc. from April 1999 to May 2005, and as a Financial Analyst at Qualcomm Incorporated from June 1997 to April 1999.Ms. Forbes holds a B.S. in Business Administration from San Diego State University.

Mr. Moglia, age 53, joined Orexigen in April 2008 and has served as its Vice President and Chief Accounting Officer since February 2015, having previously served as its Senior Director of Financial Reporting and Controller from April 2008 to February 2015.Prior to joining Orexigen, Mr. Moglia served as Director of SEC Reporting and Compliance at Biosite, Inc. from May 2003 to August 2007, as Controller at Alliance Pharmaceuticals from June 1997 to April 2003, and as Controller at the Burnham Institute from May 1991 to May 1997.Mr. Moglia also served as a Senior Accountant with Ernst and Young LLP from September 1988 to April 1991. Mr. Moglia is a certified public accountant (inactive) in the state of California and holds a B.S. in Business Administration from San Diego State University.

In connection with Ms. Forbes’ promotion to Vice President and acting Chief Financial Officer and appointment as principal financial officer, the Company approved an increase in her annual base salary to $250,000 and an increase in her annual performance bonus target to 50%.The Company also approved the entry with Ms. Forbes into its forms of Executive Officer Employment Agreement and Director and Executive Officer Indemnification Agreement, forms of which have been previously filed as exhibits to the Company’s periodic reports with the Securities and Exchange Commission.

In connection with Mr. Moglia’s appointment as principal accounting officer, the Company approved an increase in his annual base salary to $275,000.

About OREXIGEN THERAPEUTICS, Inc. (NASDAQ:OREX)

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.